Retroviral transduction of human CD34(+) umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA Journal Article


Authors: Flasshove, M.; Banerjee, D.; Leonard, J. P.; Mineishi, S.; Li, M. X.; Bertino, J. R.; Moore, M. A. S.
Article Title: Retroviral transduction of human CD34(+) umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA
Abstract: Umbilical cord blood cells (UCB) have become a major target population for experimental and clinical studies using transfer of genes involved in inborn enzymatic diseases. Cord blood contains hematopoietic progenitor cells at a high frequency, and expanding these cells ex vivo generates sufficient numbers of hematopoietic precursors for transplantation into adults, e.g., as supportive treatment. As clinical reports about retroviral transduction into UCB cells have not been as encouraging as the first preclinical data, we have established a retroviral transduction system that allows expansion and selection of hematopoietic progenitor cells from UCB. CD34-enriched UCB cells were transduced with a retroviral vector encoding a mutated dihydrofolate reductase cDNA that confers MTX resistance. We observed increased resistance to MTX in transduced granulocyte macrophage-colony forming units (CFU-GM) after co-culture of CD34+ UCB cells with the virus-producing cell line, or after incubation with virus-containing supernatant. The supernatant-based transduction protocol included a prestimulation with recombinant interleukin-1 (rhIL-1), rhkit-ligand, and rhIL-3 to increase the percentage of cells in S phase to greater than 50%. Using this protocol we measured a 72-fold expansion of CFU-GM and a 2.5-fold selective advantage of transduced versus nontransduced progenitor cells after exposure to low-dose methotrexate in liquid culture. Polymerase chain reaction analysis revealed integration of proviral DNA into the majority of transduced colonies before and after ex vivo expansion. The retroviral vector and transduction protocol reported here provides an experimental system for selection and expansion of retrovirally transduced progenitor/stem cells from UCB that may help improve the efficiency of current clinical gene therapy strategies.
Keywords: controlled study; human cell; mutation; nonhuman; methotrexate; polymerase chain reaction; cell cycle s phase; cd34 antigen; stem cell factor; drug resistance; gene transfer; genetic transduction; genetic vectors; fetal blood; hematopoietic stem cells; umbilical cord blood; hematopoietic stem cell; dihydrofolate reductase; folic acid antagonists; tetrahydrofolate dehydrogenase; antigens, cd34; s phase; complementary dna; retrovirus; retroviridae; colony forming unit gm; dna, complementary; gene transfer techniques; interleukin 1; coculture; virus dna; dna integration; interleukin 3; humans; human; article; provirus; proviruses
Journal Title: Human Gene Therapy
Volume: 9
Issue: 1
ISSN: 1043-0342
Publisher: Mary Ann Liebert, Inc  
Date Published: 1998-01-01
Start Page: 63
End Page: 71
Language: English
PUBMED: 9458243
PROVIDER: scopus
DOI: 10.1089/hum.1998.9.1-63
DOI/URL:
Notes: Article -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Debabrata Banerjee
    136 Banerjee
  2. Joseph Bertino
    363 Bertino
  3. Malcolm A S Moore
    549 Moore